Biomarker update for breast, colorectal and non-small cell lung cancer.
The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.